U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H25N
Molecular Weight 291.4299
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MELITRACEN

SMILES

CN(C)CCC=C1C2=C(C=CC=C2)C(C)(C)C3=C1C=CC=C3

InChI

InChIKey=GWWLWDURRGNSRS-UHFFFAOYSA-N
InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3

HIDE SMILES / InChI
Molecular Formula C21H25N
Molecular Weight 291.4299
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.aci-bd.com/Brand/Adelax.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18331614

Melitracen (HCl) is a tricyclic antidepressant with actions and effects similar to amitriptyline.Melitracen (HCl) is given orally in the treatment of depression. It should be withdrawn gradually to reduce the risk of withdrawl symptoms. Melitracen (HCl) is primarily indicated in conditions like Anxiety, Asthenia, Depression, gastro-intestinal disorders associated with anxiety and agitation. Melitracen is marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol. The way this drug works hasn’t been thoroughly researched, but some hypothesize that it may work similarly to the drugs Imipramine and Amitriptyline. In comparison to older TCAs, this drug is thought to work more quickly with more favorable side effects.

CNS Activity

CNS Active
3913
Curator's Comment: Melitracen acts in the brain

Originator

Kefalas
3
Curator's Comment: Melitracen was patented in 1963 by Kefalas A/S

Approval Year

Unknown
139594
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
Primary
Approved
8429
Deanxit

Approved Use

Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.

Launch Date

8.8361278E11
PubMed

PubMed

TitleDatePubMed
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
2005 Dec 9
Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method.
2006 Oct 16
Validation of a sensitive LC/MS/MS method for simultaneous quantitation of flupentixol and melitracene in human plasma.
2007 Dec 21
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.
2007 Dec 28
Purple urine bag syndrome in nursing homes: ten elderly case reports and a literature review.
2008
Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia.
2008 Jun 1
[Efficacy and safety of Deanxit combined with Wuling Capsule in treating post-stroke depression: a randomized controlled trial].
2008 Mar
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.
2009 Nov
[Study on catgut implantation therapy compared with Deanxit for treatment of depression].
2010 Aug
[Comparative study on abdominal acupuncture and western medicine for treatment of menopause depressive disorder].
2010 Nov
Patents

Patents

CN100560064C
3
CN103877088A
3
CN104288153A
3
EP2374450 A1
3

Sample Use Guides

In Vivo Use Guide
Oral Depression Adult: Initially, 25 mg bid-tid, gradually increased to 225 mg daily if necessary. Elderly: Initially, 25 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:05:29 UTC 2023
Edited
by admin
on Fri Dec 15 15:05:29 UTC 2023
Record UNII
Q7T0Y1109Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MELITRACEN
INN   MI   WHO-DD  
INN  
Official Name English
1-PROPANAMINE, 3-(10,10-DIMETHYL-9(10H)-ANTHRACENYLIDENE)-N,N-DIMETHYL-
Systematic Name English
ADELAX
Brand Name English
melitracen [INN]
Common Name English
MELITRACEN [MI]
Common Name English
Melitracen [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QN06CA02
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
WHO-ATC N06AA14
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
WHO-VATC QN06AA14
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
WHO-ATC N06CA02
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
Code System Code Type Description
PUBCHEM
25382
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
ECHA (EC/EINECS)
225-858-5
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
SMS_ID
100000081448
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
ChEMBL
CHEMBL110094
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
WIKIPEDIA
MELITRACEN
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
MERCK INDEX
m7161
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY Merck Index
CAS
5118-29-6
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
NCI_THESAURUS
C174875
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
EVMPD
SUB08725MIG
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
DRUG BANK
DB13384
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
RXCUI
446248
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID4048274
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
DRUG CENTRAL
1675
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
FDA UNII
Q7T0Y1109Z
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
INN
1568
Created by admin on Fri Dec 15 15:05:29 UTC 2023 , Edited by admin on Fri Dec 15 15:05:29 UTC 2023
PRIMARY
Related Record Type Details
Structure of MELITRACEN METHANESULFONATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of MELITRACEN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966